-

DMRC INVESTOR ALERT: Kirby McInerney LLP Notifies Digimarc Corporation Investors of Upcoming Lead Plaintiff Deadline in Class Action Lawsuit

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds investors of the July 8, 2025, deadline to seek the role of lead plaintiff in a federal securities class action filed on behalf of investors who acquired Digimarc Corporation (“Digimarc” or the “Company”) (NASDAQ:DMRC) securities during the period from May 3, 2024, through February 26, 2025 (“the Class Period”).

[LEARN MORE ABOUT THE CLASS ACTION]

On February 26, 2025, Digimarc announced its financial results for the fourth quarter and the full year of 2024. The Company reported a 10% drop in quarterly subscription revenue, down to $5.0 million from $5.6 million the previous year, and a decrease in annual recurring revenue to $20.0 million from $22.23 million the prior year. These declines “primarily reflect[ed] a $5.8 million decrease in ARR due to the expiration of a commercial contract in June 2024.” On this news, the price of Digimarc shares declined by $11.65 per share, or approximately 43%, from $27.04 per share on February 26, 2025, to close at $15.39 on February 27, 2025.

The complaint alleges that defendants, throughout the Class Period, failed to disclose that: (1) that a large commercial partner would not renew a large contract on the same terms; (2) that, as a result, Digimarc would renegotiate the large commercial contract; and (3) that, as a result of the foregoing, the Company’s subscription revenue and annual recurring revenue would be adversely affected.

If you purchased or otherwise acquired Digimarc securities, have information, or would like to learn more about this investigation, please contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the form below, to discuss your rights or interests with respect to these matters without any cost to you.

[CONTACT FORM]

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-699-1180
https://www.kmllp.com
investigations@kmllp.com

Kirby McInerney LLP

NASDAQ:DMRC

Release Versions
$Cashtags

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-699-1180
https://www.kmllp.com
investigations@kmllp.com

More News From Kirby McInerney LLP

INVESTOR ALERT: Securities Class Action Filed Against Aldeyra Therapeutics – Investors Encouraged to Contact Kirby McInerney LLP

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Aldeyra Therapeutics (“Aldeyra” or the “Company”) (NASDAQ:ALDX) securities during the period of November 3, 2023 through March 16, 2026, inclusive (“the Class Period”). If you suffered a loss on your Aldeyra investments, you have until May 29, 2026 to request lead plaintiff appointment. Courts do not consider lead plaintiff applications submitte...

VITAL FARMS, INC. ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Investors

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Vital Farms, Inc. (“Vital Farms” or the “Company”) (NASDAQ:VITL) securities during the period of May 8, 2025 through February 26, 2026, inclusive (“the Class Period”). If you suffered a loss on your Vital Farms investments, you have until May 26, 2026 to request lead plaintiff appointment. For more information: [CONTACT THE FIRM IF YOU SUFFERED...

ADMA BIOLOGICS, INC. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ:ADMA). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On March 24, 2026, Culper Research published a report on ADMA alleging “Channel Stuffing, an Undisclos...
Back to Newsroom